



PREPARATION AND CHARACTERISATION OF CTAB
AND CHITOSAN MODIFIED PLGA NANOPARTICLES
CONTAINING PLASMID DNA AND NIGELLA SATIVA
OIL FOR ALZHEIMER DISEASE

BY

ABD ALMONEM DOOLAANEAA

A thesis submitted in fulfilment of the requirement for the
degree of Doctor of Philosophy in Pharmaceutical Science
(Pharmaceutical Technology)

Kulliyyah of Pharmacy
International Islamic University Malaysia

NOVEMBER 2014

ABSTRACT

Background: Alzheimer's disease (AD) is spreading in both developed and developing countries with no comprehensive treatment. Gene therapy provides new treatment strategies where it can interfere the disease on its genetic levels. Viral gene therapy is currently in clinical trial stage but it is facing problems due to safety issues. *Nigella sativa* is an herbal and Prophet medicine having numerous medical effects in AD and other diseases. CTAB and chitosan are frequently used in the preparation of nanoparticle for non-viral gene therapy. **Objective:** To co-encapsulate NSO with pDNA in one gene delivery system based on PLGA nanoparticles for the treatment of AD. **Methodology:** We fabricated PLGA microspheres loaded with pDNA using double-emulsion solvent-evaporation method and investigated the effect of surfactants and PLGA. *N. sativa* oil (NSO) was encapsulated in PLGA microparticle and its cell uptake was evaluated using PC-12 cell line. Two approaches were applied in co-encapsulating pDNA with NSO in one PLGA nanoparticle system i.e. adsorption on pre-prepared cationic nanoparticles and encapsulation within nanoparticles after being complexed with CTAB. CTAB and chitosan-modified PLGA nanoparticles were fabricated and then incorporated with pDNA. NSO was co-encapsulated with pDNA either by adsorption on chitosan-modified nanoparticles or by encapsulation. NSO encapsulation efficiency was evaluated using FTIR. The neuroregenerative effect of the encapsulated NSO was evaluated on N2a cells. **Results and discussion:** Tween blend of HLB-16 revealed the highest supercoil preservation index. Span surfactant and carboxyl terminal low molecular weight PLGA, Tween blend of HLB-16, Triton X-100 revealed exhibited high, moderate and low burst release, respectively. NSO-loaded PLGA microparticles were taken up mainly by mitotic cells in a similar efficiency to Span-modified microparticles but less than Tween 80-modified microparticles. CTAB-modified PLGA nanoparticles were negatively charged while chitosan-PLGA nanoparticles were positively charged. Chitosan-PLGA nanoparticles were taken up by N2a cells higher than other formulations and exhibited good transfection efficiency after being loaded with pDNA. Meanwhile, CTAB-pDNA-PLGA nanoparticles showed the highest transfection efficiency with low burst release. The developed FTIR method exhibited linearity in the range of NSO/PLGA of 5-150%. Both NSO and pDNA were encapsulated in PLGA nanoparticles. NSO encapsulation efficiency was lower in chitosan-modified nanoparticles. The encapsulated pDNA and NSO exhibited the desirable effects in N2a cells. The encapsulated pDNA exhibited the ex-gene expression of green fluorescent protein whereas the encapsulated NSO exhibited neurite outgrowth effect. **Conclusion:** NSO was successfully co-encapsulated with pDNA in PLGA nanoparticles as non-viral gene delivery system. The gene expression from the encapsulated pDNA, the encapsulated NSO was able to exhibit neuroregeneration in N2a cells. CTAB-pDNA-NSO-PLGA nanoparticles revealed the best results with slower pDNA release and higher neurite outgrowth effect.

ملخص البحث

خلفية البحث: تزداد وتيرة حدوث مرض الزهايمر مع عدم وجود علاج فعال. يشكل العلاج الوراثي طريقة جديدة للتفاعل مع المرض على المستوى الوراثي. التجارب السريرية للعلاج الوراثي لمرض ألزهايمر تستخدم فيروسات لكنها مرتبطة بمشاكل صحية. حبة السوداء هي نبات طبي ومن الطب النبوي له تأثيرات طبية عديدة في مرض ألزهايمر وغيره. يستخدم الكيتوزان والCTAB في تحضير الجسيمات النانوية للعلاج الوراثي اللافيروسي. **هدف البحث:** تغليف الدنا وزيت حبة السوداء في شكل نانوي واحد لمعالجة مرض ألزهايمر. **طريقة البحث:** في هذه الدراسة قمنا بتصنيع جسيمات مكرونية من الPLGA محملة بالبلاسميد ودرسنا تأثير البوليمير والعديد من العوامل الفاعلة على السطح. أظهرت الدراسة أن خليط التوين ذا الHLB 16 له أكبر قيمة لحفظ البلاسميد. دراسة التحرر الميديد بينت أن مركبات السبان أدت إلى تحرر سريع بينما التريتون أدى إلى تحرر بطيء والتوين بينهما. قمنا بتحضير جسيمات مكرونية من زيت حبة السوداء والبوليمير المذكور أعلاه و قمت دراسة القبض الخلوي لهذه الجسيمات من قبل خلايا الPC-12. أظهرت النتائج أن هذه الجسيمات تم قبضها من قبل الخلايا الانقسامية وبشكل أقل من الجسيمات المعدلة بالتوين 80. بعد ذلك هدفت الدراسة لتحضير جسيمات نانوية تضم البلاسميد وزيت حبة السوداء معاً. تم ذلك بطريقتين إما بادمصاص البلاسميد على جسيمات نانوية معدلة بالكيتوزان أو الCTAB أو تغليف البلازميد وحبة السوداء معاً. **النتائج والمناقشة:** الCTAB على عكس الكيتوزان لم يعط الجسيمات شحنة موجبة. الجسيمات المعدلة بالكيتوزان تم قبضها بشكل أكبر من قبل الخلايا العصبية (N2a) وأظهرت تعبيراً جينياً جيداً. في المقابل، الجسيمات التي تضمنت البلاسميد داخلها أظهرت أعلى درجة من التعبير الجيني. التحديد الكمي لزيت حبة السوداء أظهر خطية في المجال 5-150%. كلا البلاسميد وزيت حبة السوداء أظهرتا التأثيرات الدوائية المطلوبة حيث أدى البلاسميد إلى التعبير الجيني للمورثة الجديدة بينما حرض زيت الحبة السوداء على نمو الامتدادات العصبية للخلايا. **الخلاصة:** من الممكن تغليف زيت حبة السوداء والبلاسميد معاً في جسيمات نانوية واحدة مع المحافظة على فعاليتها. إضافة الزيت له تأثير داعم في معالجة مرض ألزهايمر. الكبسلة المشتركة معاً تملك الخصائص الأفضل والأكثر ثباتاً.

APPROVAL PAGE

The thesis of Abd Almonem Doolaanea has been approved by the following:

Farahidah Mohamed
Supervisor

Muhammad Taher
Internal Examiner

Peh Kok Khiang
External Examiner

Saringat Haji Baie
External Examiner

Abdul Kabir Hussain Solihu
Chairman

DECLARATION

I hereby declare that this thesis is the result of my own investigation, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Abd Almonem Doolaanea

Signature.....

Date

INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

**DECLARATION OF COPYRIGHT AND AFFIRMATION
OF FAIR USE OF UNPUBLISHED RESEARCH**

Copyright ©2014 by International Islamic University Malaysia. All rights reserved.

**PREPARATION AND CHARACTERISATION OF CTAB AND
CHITOSAN MODIFIED PLGA NANOPARTICLES CONTAINING
PLASMID DNA AND NIGELLA SATIVA OIL FOR ALZHEIMER
DISEASE**

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below.

1. Any material contained in or derived from this unpublished research may be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.
3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

Affirmed by Abd Almonem Doolaanea

.....
Signature

.....
Date

To my grandfather, my parents and my wife...

ACKNOWLEDGEMENTS

Alhamdulillah. I thank Allah for the help throughout the study and for giving the knowledge and patience.

I thank Prophet Muhammad (S.A.W) for guiding me to the correct way.

I thank my father (Khalid Doolaanea) and mother (Fatimah Almohammad) for all the support and doa` from far away as if I am with them.

I thank my wife (Dima Almohammad) for her great support and accompanying me at each step. I thank my daughters (Mays & Leen) who inspired me with the spirit of relief and comfort.

I thank all my family members with special thanks to Grandfather Abd ALMONEM Doolaanea, Uncle Zuhir Doolaanea and Uncle Safwan Almohammad.

I thank and appreciate the help from my supervisor, my colleagues and lab mates.

I thank International Islamic University Malaysia (IIUM) for the fund EDW-B10-100-0439 and Ministry of Science, Technology and Innovation (Malaysia) for the fund 02-01-08-SF0101.

I thank Aleppo University where I spent great time and acquired a lot of knowledge.

TABLE OF CONTENTS

Abstract	ii
Abstract in Arabic	iii
Approval page	iv
Declaration	v
Copyright Page	vi
Dedication	vii
Acknowledgements	viii
List of Tables	xiv
List of Figures	xvi
List of Equations	xxi
List of Abbreviations	xxii
CHAPTER ONE: INTRODUCTION	1
1.1 Problem statement	1
1.2 Scope and objectives	1
1.3 Hypothesis	2
1.4 Brief explanation on the flow of experiments	3
CHAPTER TWO: LITERATURE REVIEW	5
2.1 Historical updates on gene therapy	5
2.2 Plasmid DNA in gene therapy	6
2.2.1 Basic Plasmid Characteristics	8
2.2.2 Some Common Criteria for a Cloning Vector	9
2.2.2.1 Selectable Marker	9
2.2.2.2 Reporter genes	10
2.3 Alzheimer disease	11
2.3.1 An Overview	11
2.3.2 Causes of Alzheimer Disease	12
2.3.2.1 Risk Factors	13
2.3.2.2 Genetic Implications	13
2.3.3 Treatment of Alzheimer Disease	14
2.3.3.1 Approved Drugs	14
2.3.3.2 Clinical Trials	15
2.3.4 Natural Products in Alzheimer Disease	17
2.3.5 <i>Nigella sativa</i> in Alzheimer Disease and Other Diseases	18
2.3.5.1 Overview and Chemical Composition	18
2.3.5.2 <i>N. sativa</i> Pharmacological Effects	20
2.3.6 Gene Therapy Clinical Trials for Alzheimer Disease	22
2.3.6.1 NCT00017940	25
2.3.6.2 NCT00087789	25
2.3.6.3 NCT00876863	25
2.3.6.4 NCT01163825	26
2.3.7 Blood Brain Barrier and Its Implications in Alzheimer Disease and Drug Delivery into the Brain	26
2.4 Microencapsulation	29

2.4.1 History.....	29
2.4.2 Fabrication techniques	31
2.4.2.1 Solvent Evaporation	31
2.4.2.2 Spontaneous Emulsification/Solvent Diffusion.....	33
2.4.2.3 Other Methods	33
2.4.3 Applicable Polymers in Micro/Nanoencapsulation Process	33
2.4.3.1 Polyesters.....	34
2.4.3.2 Polyanhydrides	35
2.4.4 Drug Loading	35
2.4.5 Characterisation of Micro/Nanoparticles	35
2.4.5.1 Particle Size	35
2.4.5.2 Surface Properties.....	36
2.4.5.3 Differential Scanning Calorimetry (DSC).....	37
2.4.5.4 In Vitro Release	37
2.5 Surfactants in micro/nanoencapsulation	38
2.5.1 Definition	38
2.5.2 Surfactant Types.....	39
2.5.2.1 Anionic Surfactants	39
2.5.2.2 Cationic Surfactants.....	39
2.5.2.3 Non-ionic Surfactants	40
2.5.2.4 Zwitterionic Surfactants	40
2.5.3 HLB Concept	40
2.5.4 Application of Surfactants in Micro/Nanoparticle Drug Delivery.....	41
2.6 PLGA in drug delivery.....	44
2.6.1 PLGA Composition.....	44
2.6.2 PLGA Variations.....	44
2.6.3 PLGA Degradation and Drug Release from PLGA Matrix.....	44
2.6.4 PLGA Pharmaceutical and Biomedical Applications	46
2.6.4.1 Tissue Engineering	47
2.6.4.2 Diagnosis (Imaging)	48
2.6.4.3 Cancer.....	48
2.6.4.4 Immunology and Vaccines	49
2.6.4.5 Diabetes Mellitus.....	49
2.6.4.6 Drug Delivery to the Brain	50
2.6.4.7 Eye Drug Delivery.....	50
2.7 Chitosan in drug delivery	51
2.7.1 Physicochemical Properties and Structure–Property Relationship	51
2.7.2 Chitosan Biocompatibility	53
2.7.3 Chitosan Pharmaceutical and Biomedical Applications	54
2.7.3.1 Tissue Engineering	54
2.7.3.2 Wound Healing.....	54
2.7.3.3 Drug Delivery	55
2.7.3.4 Gene Therapy	55
2.7.3.5 Enhancement Effect on BBB Permeation	56
2.7.3.6 Chitosan-PLGA Nanoparticles for Gene Therapy.....	56

CHAPTER THREE: EFFECT OF SURFACTANTS AND PLGA MOLECULAR WEIGHT AND HYDROPHOBICITY ON PLASMID DNA PRESERVATION BASED ON SUPERCOIL INDEX.....	58
3.1 Introduction	58
3.2 Materials and methods	59
3.2.1 Materials.....	59
3.2.2 pDNA Preparation and Isoform Analysis	60
3.2.3 Evaluation of the pseudo-primary emulsion stability	62
3.2.4 Fabrication of pDNA-loaded PLGA Microspheres	63
3.2.4.1 Surfactant or Surfactant Blends as Variable.....	63
3.2.4.2 PLGA MW and Relative Hydrophobicity as Variables ..	64
3.2.5 Characterisation of pDNA-loaded PLGA Microspheres	65
3.2.5.1 Particle Size	65
3.2.5.2 Surface Morphology	65
3.2.5.3 Encapsulation and Supercoil Preservation Efficiency.....	65
3.2.5.4 Supercoil Index (SCI).....	65
3.2.5.5 Thermal Analysis.....	66
3.2.6 <i>In Vitro</i> Release Profile.....	66
3.2.7 Statistical analysis	67
3.3 Results and discussion.....	67
3.3.1 Pseudo-primary Emulsion Stability	67
3.3.2 Effect of Surfactants on pDNA-loaded PLGA Microspheres.....	68
3.3.2.1 Microsphere Particle Size and Surface Morphology	68
3.3.2.2 Microsphere Encapsulation Efficiency.....	72
3.3.2.3 Plasmid Stability (SC Preservation) and Glass Transition.....	74
3.3.2.4 Supercoil Index (SCI).....	78
3.3.3 Effect of PLGA MW and Hydrophobicity on pDNA-loaded PLGA Microspheres.....	79
3.3.3.1 Microsphere Particle Size and Surface Morphology	79
3.3.3.2 Microsphere Encapsulation Efficiency.....	81
3.3.3.3 Plasmid Stability (SC Preservation)	82
3.3.3.4 Supercoil Index (SCI).....	83
3.3.4 Release profile.....	83
3.3.4.1 Effect of Surfactants on the Release.....	86
3.3.4.2 Effect of PLGA on the Release	87
3.4 Conclusion.....	89
CHAPTER FOUR: CELL UPTAKE OF NIGELLA SATIVA OIL PLGA MICROPARTICLE BY PC-12 CELL LINE.....	90
4.1 Introduction	90
4.2 Materials and methods	92
4.2.1 Materials.....	92
4.2.2 Fabrication of Microparticle	92
4.2.3 Characterization of the Microparticles.....	94
4.2.3.1 Particle Size Analysis	94
4.2.3.2 Surface Morphology	94
4.2.3.3 Zeta Potential Analysis	94
4.2.4 Cell Culture and Cellular Uptake Measurement	95

4.2.4.1 Total cell protein.....	95
4.2.4.2 Quantification of the Cellular Uptake Efficiency.....	96
4.2.5 Statistical Analysis.....	98
4.3 Results and discussion.....	98
4.4 Conclusion.....	111

CHAPTER FIVE: A COMPARATIVE STUDY BETWEEN PLASMID DNA ADSORPTION ON CTAB/CHITOSAN PLGA NANOPARTICLES AND ENCAPSULATION WITHIN PLGA NANOPARTICLES..... 112

5.1 Introduction.....	112
5.2 Materials and methods.....	114
5.2.1 Materials.....	114
5.2.2 Nanoparticle Fabrication.....	114
5.2.3 Nanoparticle Characterisation.....	118
5.2.3.1 Particle Size and Zeta Potential and Conductivity Measurements.....	118
5.2.3.2 Thermal Analysis by DSC.....	118
5.2.3.3 Cytotoxicity of Nanoparticles.....	119
5.2.3.4 Loading Efficiency of pDNA (F5).....	119
5.2.3.5 Nanoparticle Suspension Stability.....	120
5.2.3.6 Scanning Electron Microscopy.....	120
5.2.3.7 Fourier Transform Infrared Spectroscopy.....	120
5.2.4 Preparation and Characterisation of Nanoparticle-pDNA (NP-pDNA) Complexes.....	121
5.2.5 Release Profile.....	121
5.2.6 Cell Uptake of Nanoparticles by N2a Cells.....	122
5.2.7 Transfection Efficiency.....	122
5.2.8 Statistical analysis.....	123
5.3 Results and discussion.....	123
5.3.1 Characterisation of Nanoparticles.....	123
5.3.1.1 Particle Size.....	123
5.3.1.2 Zeta Potential and Conductivity.....	129
5.3.1.3 DSC Characterisation of Formulations F1-4.....	136
5.3.1.4 Cytotoxicity of the CTAB/Chitosan-modified Nanoparticles.....	146
5.3.1.5 Loading Efficiency of pDNA (in Formulation F5).....	148
5.3.1.6 Nanoparticle Suspension Stability.....	150
5.3.1.7 Scanning Electron Microscopy.....	151
5.3.1.8 Fourier Transform Infrared Spectroscopy.....	152
5.3.2 Characterisation of NP-pDNA Complexes.....	154
5.3.3 <i>In Vitro</i> Release Profile.....	158
5.3.4 Cell Uptake of Nanoparticles by N2a Cells.....	160
5.3.5 Transfection of N2a Cells.....	163
5.4 Conclusion.....	167

CHAPTER SIX: CO-ENCAPSULATION OF NIGELLA SATIVA OIL AND PLASMID DNA FOR ENHANCED GENE THERAPY OF ALZHEIMER DISEASE..... 168

6.1 Introduction.....	168
-----------------------	-----

6.2 Materials and methods	169
6.2.1 Materials.....	169
6.2.2 Nanoparticle Preparation.....	169
6.2.3 Nanoparticle Characterisation.....	170
6.2.3.1 Particle Size and Zeta Potential.....	170
6.2.3.2 Suspension stability.....	170
6.2.3.3 Scanning electron microscopy.....	170
6.2.3.4 Differential scanning calorimetry.....	170
6.2.4 Loading Efficiency.....	171
6.2.4.1 Loading Efficiency of pDNA.....	171
6.2.4.2 Loading Efficiency of NSO.....	171
6.2.5 Preparation and Characterisation of NP-pDNA Complex.....	176
6.2.6 Release Profile.....	176
6.2.7 Nanoparticles Cytotoxicity.....	176
6.2.8 Cell uptake of nanoparticles.....	176
6.2.9 Transfection efficiency (gene expression of GFP).....	176
6.2.10 Effect of the Encapsulated NSO on Neurite Outgrowth of N2a Cells.....	177
6.2.11 Statistical analysis.....	177
6.3 Results and discussion	177
6.3.1 Characterisation of Nanoparticles.....	177
6.3.1.1 Particle Size.....	177
6.3.1.2 Zeta Potential.....	180
6.3.1.3 Suspension Stability.....	185
6.3.1.4 Scanning Electron Microscopy.....	186
6.3.1.5 Differential Scanning Calorimetry.....	187
6.3.2 Loading Efficiency.....	190
6.3.2.1 Loading Efficiency of pDNA (F3).....	190
6.3.2.2 Loading Efficiency of NSO.....	190
6.3.3 NP-pDNA Complex Preparation and Characterisation.....	197
6.3.3.1 Agarose Gel Retardation and Zeta Potential.....	197
6.3.3.2 Stability of the Adsorbed or Encapsulated pDNA in the Presence of Serum.....	200
6.3.4 <i>In Vitro</i> Release Profile.....	201
6.3.5 Cytotoxicity.....	202
6.3.6 Cellular Uptake by N2a Cells.....	203
6.3.7 Transfection of N2a Cells.....	205
6.3.8 The Neuroregeneration Effect of the Encapsulated NSO: Promoting Neurite Outgrowth of N2a Cells.....	209
6.4 Conclusion.....	212

CHAPTER SEVEN: GENERAL CONCLUSION AND RECOMMENDATIONS.....	213
7.1 General Conclusion.....	213
7.2 recommendations.....	215
BIBLIOGRAPHY.....	217
APPENDIX I PUBLICATIONS AND PATENTS.....	239

LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
2.1	Some commonly used cloning vectors and their key features (Preston, 2003).	8
2.2	Some reporter genes commonly used in bacterial systems (Liu, 2003).	11
2.3	Gene therapy clinical trials for AD.	24
2.4	Example of some PLGA formulations that entered the market (Wischke & Schwendeman, 2008).	47
2.5	Example of some PLGA formulations in development stage (Danhier et al., 2012).	47
2.6	Relationship between chitosan structural parameters and properties (Dash et al., 2011).	52
3.1	The blends of surfactants that used in the emulsion stability and microsphere fabrication.	62
3.2	Effect of different surfactants and surfactant blends on physical characteristics of pDNA-loaded PLGA microspheres.	69
3.3	Effect of PLGA MW and hydrophobicity on pDNA-loaded PLGA microspheres.	79
4.1	Formulation of the PLGA microparticles loaded with NSO and different surfactants.	93
4.2	Particle size and polydispersity index (span value) of the microparticles fabricated with different surfactants and NSO.	101
5.1	Contents of different nanoparticle formulations.	115
5.2	Glass transitions of PLGA in different blends and formulations.	136
5.3	DSC peaks of PLGA, PVA, CTAB, and chitosan acetate.	138
6.1	Contents of the three nanoparticle formulations.	170
6.2	Selected peaks from FTIR spectra of the NSO-PLGA standard mixtures in order to construct the best standard curve.	174

6.3	Selected peaks from 2 nd and 3 rd derivatives of FTIR spectra of the NSO-PLGA standard mixtures in order to construct the best standard curve.	174
6.4	DSC results including T_g for PLGA and chitosan in addition to the transition of NSO.	188
6.5	The results of different peaks' selections that explained in Table 6.2 and Table 6.3.	194

LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Vectors used in gene therapy clinical trials.	7
2.2	Schematic representation of the relative migration of different forms of pDNA in ethidium bromide pre- and post-stained agarose gels.	9
2.3	pGL3 Control Vector (Promega, Medison, WI).	10
2.4	Number of clinical trials on ‘Alzheimer disease’ in the world with zooming on Southeast Asia.	16
2.5	<i>Nigella sativa</i> plant, flower and seeds.	19
2.6	Schematic representation of the blood–brain barrier (BBB) and other components of a neurovascular unit.	27
2.7	Methods of the transport across the BBB.	29
2.8	Structure of the different types of polymer nanoparticles.	30
2.9	Schematic diagram of (A) single and (B) double emulsion techniques for nanoparticle fabrication and (C) the proposed mechanism of nanocapsule formation by emulsification (i) followed by solvent extraction (ii).	32
2.10	Chemical structures of PLA, PGA and their copolymer PLGA.	34
2.11	Chemical structures of <i>N</i> -acetyl- β -D-glucosamine units, D-glucosamine units and partially acetylated chitosan.	51
3.1	Chemical structures of the different surfactants evaluated in this study.	60
3.2	Schematic diagram representing the method of pDNA purification.	61
3.3	Schematic diagram representing the method of microsphere fabrication.	63
3.4	Screening of pseudo-primary emulsion stability.	68
3.5	SEM images showing the surface morphology of pDNA-loaded PLGA microspheres prepared with different surfactants.	71
3.6	Representative diagram for the reverse micelles.	72

3.7	Agarose gel electrophoresis for the pDNA extracted from the microspheres prepared with different surfactants.	75
3.8	Effect of surfactants on glass transition temperature (T_g) of the microspheres.	77
3.9	SEM images showing the surface morphology of pDNA-loaded PLGA microspheres prepared with different PLGAs.	80
3.10	Agarose gel electrophoresis for the pDNA extracted from pDNA-loaded PLGA microspheres prepared with different PLGAs.	83
3.11	Release profile of pDNA from the microspheres prepared by various surfactants and PLGAs.	85
3.12	SEM images of the microspheres at (Day 0), Day 1 and Day 28 of the release.	87
4.1	Schematic diagram representing the method of fabrication of microparticles.	93
4.2	Schematic diagram representing the method of quantification of the cell uptake.	97
4.3	Standard curves of the fluorescence intensity against microparticle concentrations.	98
4.4	Particle size distribution of PLGA microparticles fabricated with NSO and other surfactants.	100
4.5	SEM images for PLGA microparticles fabricated with NSO and other surfactants.	102
4.6	Zeta potential for PLGA microparticles fabricated with NSO and different surfactants.	103
4.7	Quantification of cellular uptake of microparticles by PC-12 cells.	106
4.8	Cell uptake of NSO- and Tween 80-modified microparticles by PC-12 cell line as seen by fluorescence inverted microscope.	109
5.1	Schematic diagram representing the method of nanoparticle fabrication (formulations F1-4).	116
5.2	Schematic diagram representing the method of nanoparticle fabrication (formulation F5).	117
5.3	Particle size (mean \pm standard error) of the nanoparticles suspended in deionised water or in the presence of 10% FBS and NP-pDNA ratio 20 suspended in water.	125

5.4	Particle size distribution of the nanoparticles suspended in deionized water or in the presence of 10% FBS and NP-pDNA ratio 20 suspended in water.	125
5.5	Schematic representation of conformations of adsorbed chitosan chains.	128
5.6	Zeta potential size (mean \pm standard error) of the nanoparticle formulations after suspending in water, phosphate buffer (PB), 10% FBS or after lyophilisation.	131
5.7	Schematic representation of the compression of the double layer around the nanoparticle when suspended in electrolyte solution to yield almost nil zeta potential.	132
5.8	Zeta potential of the nanoparticles in the range of pH values from 3.0 to 9.0.	135
5.9	DSC curves for PLGA, PVA and their physical mixture.	137
5.10	Thermograms for PLGA, chitosan acetate (LCS) and their physical mixtures.	139
5.11	Chemical structure of CTAB and schematic diagrams of its micelle and reversed micelle.	141
5.12	DSC thermograms for F1 and F2.	142
5.13	DSC thermograms for F3 and F4.	145
5.14	Suggested schematic diagram of the nanoparticles based on DSC, zeta potential and conductivity results.	146
5.15	Cytotoxicity of the four nanoparticle formulations on N2a cells by MTT assay.	147
5.16	Determination of the detection limit of agarose gel electrophoresis for pDNA.	149
5.17	Suspension stability of the nanoparticle formulations suspended in phosphate buffer pH 7.2 and monitored by spectrophotometer.	151
5.18	SEM images of nanoparticle formulations.	152
5.19	FTIR spectra of the lyophilised nanoparticles.	153
5.20	Gel retardation assay of the nanoparticles complexed with pDNA at different ratios. La	155
5.21	Zeta potential of the NP-pDNA complexes at different NP/pDNA ratios.	156

5.22	Protection of pDNA in NP-pDNA complexes at ratio 20 from degradation in 10% FBS.	157
5.23	Release profile of F5 and NP-pDNA complexes at ratio 20 over 2 weeks.	159
5.24	Quantification of the cell uptake of coumarine-6 loaded nanoparticles by N2a.	161
5.25	Cell uptake of coumarine-6-loaded nanoparticles by N2a as seen by fluorescence inverted microscope.	163
5.26	Transfection of N2a with pDNA (encoding GFP)-loaded nanoparticles as seen by fluorescence inverted microscope 48 h post-transfection.	165
5.27	Transfection of N2a with pDNA (encoding GFP)-loaded nanoparticles after image processing of the green colour area.	166
6.1	(A) Particle size and span values (numbers over the bars) of nanoparticles. (B) Particle size distribution.	178
6.2	Zeta potential of the three nanoparticle formulations in different media.	181
6.3	Zeta potential of the three nanoparticle formulations at different pH values from 3.0 to 9.0.	183
6.4	Suspension stability of the nanoparticle formulations suspended in phosphate buffer pH 7.2 and monitored by spectrophotometer.	185
6.5	SEM images for nanoparticles at different magnifications.	187
6.6	DSC cooling scan (A) and second heating scan (B) for (1) the blank formulation, (2) F1, (3) F2, (4) F3, (5) NSO, and (6) NSO-PLGA mixture.	189
6.7	FTIR spectra of the raw materials used in nanoparticle fabrication.	191
6.8	FTIR spectra of the lyophilised nanoparticles.	192
6.9	Peaks' selection from FTIR spectrum, 2 nd and 3 rd derivatives for NSO/PLGA ratio of 1.	193
6.10	FTIR spectra of the standard NSO-PLGA mixtures.	193
6.11	Standard curves obtained from FTIR spectra based on Beer-Lambert law.	195
6.12	UV spectra for dispersion medium of formulation F3 post fabrication.	197

6.13	Gel retardation assay of the nanoparticles complexed with pDNA at different ratios.	198
6.14	Zeta potential of the NP-pDNA complexes at different NP/pDNA ratios.	199
6.15	Stability of the nanoparticles loaded with pDNA in the presence of serum after 1 h and 24 h incubation.	200
6.16	Release profile of F3 and NP-pDNA complexes at ratio 20 over 2 weeks.	201
6.17	Cytotoxicity of nanoparticle formulations on N2a cells.	203
6.18	Cell uptake of nanoparticles by N2a as seen by fluorescence inverted microscope.	204
6.19	Quantitative analysis of the cell uptake by fluorescence spectrophotometer.	205
6.20	Transfection of N2a with pDNA (encoding GFP)-loaded nanoparticles as seen by fluorescence inverted microscope.	206
6.21	Transfection of N2a with pDNA (encoding GFP)-loaded nanoparticles after image processing of the green colour area.	207
6.22	Effect of NSO-loaded nanoparticles on neurite extension of N2a cells 48 h post-treatment.	210
6.23	Neurite elongation of the N2a cells treated with nanoparticles loaded with NSO.	211

LIST OF EQUATIONS

Equation 3.1	62
Equation 3.2	66
Equation 6.1	174
Equation 6.2	174
Equation 6.3	175

LIST OF ABBREVIATIONS

AAV	Adeno-associated virus
AC	Acetone
AD	Alzheimer's diseases
ApoE	Apolipoprotein E
ATCC	American Type Tissue Culture
A β	Amyloid-beta
BBB	Blood brain barrier
BCNU	1,3-bis(2-chloroethyl)-1-nitrosourea
BSA	Bovine serum albumin
CID	Compound identification number
CNS	Central nervous system
CTAB	Cetyltrimethylammonium bromide
DCM	Dichloromethane
DD	Degree of deacetylation
DLS	Dynamic light scattering
DMEM	Dulbecco's modified Eagle's medium
DMSO	Dimethyl sulfoxide
DSC	Differential scanning calorimetry
EA	Ethyl acetate
ECB	Encapsulated cell biodelivery
ECL	Effective chain length
EDTA	Ethylenediaminetetraacetic acid
EO	Ethylene oxide
FBS	Foetal bovine serum
FDA	US Food and Drug Administration
FTIR	Fourier transform infrared spectroscopy
GAA	Glacial acetic acid
GDS	Gene delivery system
GFP	Green fluorescent protein
h	hour
HLB	Hydrophile-lipophile balance
ICH	International Conference of Harmonisation
IV	Intrinsic viscosity
kb	kilobases
kDa	Kilo Daltons
LCS	Low molecular weight chitosan
MCS	Medium molecular weight chitosan
MIM	Mendelian Inheritance in Man
min	minute
miRNA	microRNA
2OMR	2'-O-methyl-RNA
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MW	Molecular weight
N2a	Murine neuroblastoma neuro 2a

NGF	Nerve growth factor
NSO	<i>Nigella sativa</i> oil
NMDA	N-methyl-D-aspartate
NP	Nanoparticle
O/W	oil/water
OC	Open circular
OMIM	Online Mendelian Inheritance in Man
OTC	Ornithine transcarbamylase
PB	Phosphate buffer
PBS	Phosphate-buffered saline
PdI	Polydispersity index
pDNA	Plasmid DNA
PEG	Polyethylene glycol
PEI	Polyethylene imine
PGA	Polyglycolic acid
PLA	Poly(lactic acid)
PLGA	Poly (lactic-co-glycolic acid)
PLL	Poly (L-lysine)
PO	Polyoxypropylene
PVA	Poly vinyl alcohol
PVP	Poly(vinyl pyrrolidone)
SC	Supercoiled
SCID	Severe combined immunodeficiency
SDS	Sodium dodecyl sulphate
SEM	Scanning electron microscopy
siRNA	Small interfering RNA
TAE	Tris-Acetate-EDTA
TE	Tris-EDTA
TEM	Transmission electron microscopy
T_g	Glass transition temperature
T_m	Melting temperature
TX	Triton X-100
UK	United Kingdom
US	United States
UV	Ultra violet
W/O	Water/oil
W/O/W	Water/oil/water
Zot	Zonula occludens toxin

CHAPTER ONE

INTRODUCTION

1.1 PROBLEM STATEMENT

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. The current AD drugs are only symptomatic with no available treatment to stop or slow down the disease. Even though the direct causes that trigger AD are unknown, it is proved that AD has genetic and non-genetic relations. Consequently, it seems rational to be treated with both gene and non-gene therapies. There is a few clinical trials using gene therapy for AD but they employ viral vectors which may have many safety issues. Non-viral gene delivery carriers are under development with noticeable success in the encapsulation plasmid DNA (pDNA). However, combining both pDNA and other therapeutic agents like *Nigella sativa* oil (NSO) in one delivery carrier is challenging. This is due to the difference in the physicochemical properties between the pDNA (very hydrophilic) and the NSO (very hydrophobic).

1.2 SCOPE AND OBJECTIVES

This study aims to develop a nanoparticle carrier to deliver both genetic element (pDNA) and non-genetic element (NSO) to the neuron cells and to evaluate the co-encapsulation of NSO in the treatment of AD. The scope and objectives of this study can be outlined as follows:

1. To fabricate pDNA-loaded PLGA microspheres and study the effects of different surfactants and PLGA molecular weights and hydrophobicities on the microspheres properties.